Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Update on Cerezyme and Fabrazyme supply from Genzyme Corporation

Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products.

24 Sep 2009

Guarding Hearts Alliance to protect quality care for patients suffering from heart disease

Organizations representing the vast majority of cardiologists around the country have joined forces today to preserve and protect the highest quality cardiac care available in America. Guarding Hearts Alliance is advocating to protect patient access to cardiac care in whatever Medicare changes or health care reform legislation is enacted.

24 Sep 2009

Acetaminophen can prevent age-related problems

Recent studies conducted by Dr. Eric Blough and his colleagues at Marshall University have shown that use of the common pain reliever acetaminophen may help prevent age-associated muscle loss and other conditions.

24 Sep 2009

AmeriCares commits to donate medicines and medical supplies to health care organizations

AmeriCares this week pledged to expand its medical assistance across the United States at the 2009 Clinton Global Initiative in New York City. AmeriCares U.S. Medical Assistance Program, announced by President & CEO Curt Welling, is a two-year commitment to improve community health by donating medicines and medical supplies to health care organizations serving the uninsured and underinsured throughout the country.

24 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Pregnancy can cause metabolic syndrome

Childbearing is associated directly with future development of the metabolic syndrome - abdominal obesity, high triglycerides, insulin resistance and other cardiovascular disease risk factors - and for women who have had gestational diabetes, the risk is more than twice greater, according to a study co-authored by University of Alabama at Birmingham (UAB) researchers published in the American Journal of Obstetrics and Gynecology.

23 Sep 2009

Celera and Medco collaborate in KIF6 gene variant testing

Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6 increases patient adherence with statin therapy. Current studies have suggested that only about 50 to 60 percent of the patients who receive a prescription for a lipid-lowering drug are taking the medication after six months.

23 Sep 2009

Women have higher incidence of stroke and mortality than men

Even though the incidence of atrial fibrillation is higher in men than women, a review of past studies and medical literature completed by cardiac experts at Rush University Medical Center shows that women are more likely than men to experience symptomatic attacks, a higher frequency of recurrences, and significantly higher heart rates during atrial fibrillation, which increases the risk of stroke.

23 Sep 2009

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the COMPLIANCE trial, a long-term study to compare external event recorders with implantable monitors in patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of post-procedure AF recurrence.

23 Sep 2009

HealthRock to promote health education

The $1 trillion cost and massive government role envisioned by the Obama Administration’s health care reform plan (The Affordable Health Choices Act of 2009) continue to create controversy in Congress and throughout the nation.

23 Sep 2009

Smoking bans result in consistent decline in heart attack rates: Study

A consistent decline in heart attack rates following the implementation of smoking bansStrongly enforced legislation to restrict smoking produces rapid and substantial reductions in community rates of heart attack, according to a meta-analysis published today in Circulation, the journal of the American Heart Association.

22 Sep 2009

Report on evidence-based disease prevention programs released by TFAH and NYAM

Trust for America's Health (TFAH) and The New York Academy of Medicine (NYAM) released a new report today featuring a range of evidence-based disease prevention programs that have shown results for improving health and reducing costs in communities.

22 Sep 2009

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highest risk for death, bivalirudin also confers the greatest mortality benefit.

22 Sep 2009

New sirolimus-eluting stent shows greater neointimal suppression than PES

A new type of sirolimus-eluting stent (SES) successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss.

22 Sep 2009

Drug-eluting stents effective for diabetic patients

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.

22 Sep 2009

Transcatheter valve implantation is an effective treatment for patients with aortic stenosis

Research presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), demonstrated an "exceptionally low" rate of complications one year after implantation of transcatheter aortic valve prostheses.

22 Sep 2009

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions (CTOs) undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

Hypertension Diagnostics' revenue decreases by 9.2% for the fiscal year 2009

Hypertension Diagnostics, Inc. (OTCBB: HDII), today announced audited financial results for the fiscal year ended June 30, 2009.

21 Sep 2009

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Update on Cerezyme and Fabrazyme supply from Genzyme Corporation

Guarding Hearts Alliance to protect quality care for patients suffering from heart disease

Acetaminophen can prevent age-related problems

AmeriCares commits to donate medicines and medical supplies to health care organizations

Research study links high-fructose diet to increased blood pressure in men

Pregnancy can cause metabolic syndrome

Celera and Medco collaborate in KIF6 gene variant testing

Women have higher incidence of stroke and mortality than men

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

HealthRock to promote health education

Smoking bans result in consistent decline in heart attack rates: Study

Report on evidence-based disease prevention programs released by TFAH and NYAM

Researchers to present results of HORIZONS-AMI trial at TCT scientific symposium

New sirolimus-eluting stent shows greater neointimal suppression than PES

Drug-eluting stents effective for diabetic patients

Update from Cannabis Science regarding its phytocannabinoid pharmaceutical products

Transcatheter valve implantation is an effective treatment for patients with aortic stenosis

Study reveals effectiveness of drug-eluting stents in treating chronic total occlusions

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

Hypertension Diagnostics' revenue decreases by 9.2% for the fiscal year 2009

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in